BioCentury | Jan 15, 2021
Politics, Policy & Law

New relevance, old guard: Biden throws weight behind science, puts Lander in Cabinet, keeps Collins at NIH

President-elect Joe Biden is raising the profile of science in his administration by elevating the role of presidential science advisor to a Cabinet position, naming the Broad Institute’s Eric Lander to the post, and nominating...
BioCentury | Jan 14, 2021
Deals

Jan. 13 Quick Takes: Takeda, KSQ enter immunotherapy deal; plus Taysha, Cardea, Esperion-Serometrix, Paion-La Jolla and more

KSQ Therapeutics Inc. granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) exclusive, global rights to develop, manufacture and commercialize cell and non-cell therapies that modulate targets identified with KSQ's CRISPRomics platform. The deal includes up to...
BioCentury | Jan 11, 2021
Finance

Immunocore raises $75M C round on back of Phase III uveal melanoma readout

On the cusp of seeking to become a commercial cancer company, Immunocore raised $75 million in a series C round. The news comes less than two months after Oxford, U.K.-based Immunocore Ltd. announced the first...
BioCentury | Dec 12, 2020
Finance

RayzeBio gets unexpected lift from broad investor appetite for targeted radiotherapies

Encountering unanticipated investor interest after closing its series A round,  RayzeBio followed up two months later with a series B raise that triples its reserves and frees the platform company from the need to make...
BioCentury | Dec 10, 2020
Product Development

Vaccines aren’t enough: COVID R&D’s adaptive platform trial aims to fill the need for new therapies

The COVID R&D Alliance is looking beyond the imminent rollout of vaccines, anticipating an ongoing need for effective therapies in hospitalized COVID-19 patients. Last week, it launched the COMMUNITY...
BioCentury | Dec 8, 2020
Product Development

ASH Monday, Biden’s picks & vaccine conundrums: a BioCentury podcast

Bispecific antibodies are top of mind at this year’s ASH meeting as they start to venture into new targets and indications in the clinic. On the latest edition of the BioCentury This Week podcast,...
BioCentury | Dec 5, 2020
Politics, Policy & Law

Trump administration uses last days to undermine public health agencies

Senior Trump administration officials are spending their last weeks in office throwing sand into the gears of government, gumming up the operation of public health agencies and dismantling protections against political interference in the actions...
BioCentury | Nov 30, 2020
Finance

Kinaset jumps into severe asthma with $40M to develop inhaled JAK inhibitor

Kinaset is launching with a $40 million series A led by  5AM Ventures and Atlas Venture with participation from Gimv to develop an inhaled immunomodulator that will compete with biologics in severe...
BioCentury | Nov 20, 2020
Finance

SR One’s newfound freedom allows firm to increase focus on company creation

SR One’s spinout from GSK gives the newly independent VC the ability to scale up what has been a top-tier investment firm over the past decade, along with the freedom to take larger stakes...
BioCentury | Nov 20, 2020
Deals

China in-licensing play LianBio follows $310M crossover round with broad Pfizer deal

Pfizer’s deal with LianBio will provide the Perceptive-backed, cross-border start-up with a commercial infrastructure in China, while giving the pharma a drug hunter and development partner led by veteran China biotech executives Bing Li and Debra...
Items per page:
1 - 10 of 1384
BioCentury | Jan 15, 2021
Politics, Policy & Law

New relevance, old guard: Biden throws weight behind science, puts Lander in Cabinet, keeps Collins at NIH

President-elect Joe Biden is raising the profile of science in his administration by elevating the role of presidential science advisor to a Cabinet position, naming the Broad Institute’s Eric Lander to the post, and nominating...
BioCentury | Jan 14, 2021
Deals

Jan. 13 Quick Takes: Takeda, KSQ enter immunotherapy deal; plus Taysha, Cardea, Esperion-Serometrix, Paion-La Jolla and more

KSQ Therapeutics Inc. granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) exclusive, global rights to develop, manufacture and commercialize cell and non-cell therapies that modulate targets identified with KSQ's CRISPRomics platform. The deal includes up to...
BioCentury | Jan 11, 2021
Finance

Immunocore raises $75M C round on back of Phase III uveal melanoma readout

On the cusp of seeking to become a commercial cancer company, Immunocore raised $75 million in a series C round. The news comes less than two months after Oxford, U.K.-based Immunocore Ltd. announced the first...
BioCentury | Dec 12, 2020
Finance

RayzeBio gets unexpected lift from broad investor appetite for targeted radiotherapies

Encountering unanticipated investor interest after closing its series A round,  RayzeBio followed up two months later with a series B raise that triples its reserves and frees the platform company from the need to make...
BioCentury | Dec 10, 2020
Product Development

Vaccines aren’t enough: COVID R&D’s adaptive platform trial aims to fill the need for new therapies

The COVID R&D Alliance is looking beyond the imminent rollout of vaccines, anticipating an ongoing need for effective therapies in hospitalized COVID-19 patients. Last week, it launched the COMMUNITY...
BioCentury | Dec 8, 2020
Product Development

ASH Monday, Biden’s picks & vaccine conundrums: a BioCentury podcast

Bispecific antibodies are top of mind at this year’s ASH meeting as they start to venture into new targets and indications in the clinic. On the latest edition of the BioCentury This Week podcast,...
BioCentury | Dec 5, 2020
Politics, Policy & Law

Trump administration uses last days to undermine public health agencies

Senior Trump administration officials are spending their last weeks in office throwing sand into the gears of government, gumming up the operation of public health agencies and dismantling protections against political interference in the actions...
BioCentury | Nov 30, 2020
Finance

Kinaset jumps into severe asthma with $40M to develop inhaled JAK inhibitor

Kinaset is launching with a $40 million series A led by  5AM Ventures and Atlas Venture with participation from Gimv to develop an inhaled immunomodulator that will compete with biologics in severe...
BioCentury | Nov 20, 2020
Finance

SR One’s newfound freedom allows firm to increase focus on company creation

SR One’s spinout from GSK gives the newly independent VC the ability to scale up what has been a top-tier investment firm over the past decade, along with the freedom to take larger stakes...
BioCentury | Nov 20, 2020
Deals

China in-licensing play LianBio follows $310M crossover round with broad Pfizer deal

Pfizer’s deal with LianBio will provide the Perceptive-backed, cross-border start-up with a commercial infrastructure in China, while giving the pharma a drug hunter and development partner led by veteran China biotech executives Bing Li and Debra...
Items per page:
1 - 10 of 1384